“To say that time below range is sufficient to measure the burden of hypoglycaemia is premature,” says Simon Heller. In this Day 2 edition of the EASD e-Learning Newsflash, he explains why conventional metrics are still important and why people living with diabetes should discuss with their clinicians what effect low glucose measurements may actually have. Richard Oram shares the most recent findings on the role of genetic factors, environmental conditions, and viral infections such as with Coxsackie B in the pathogenesis of type 1 diabetes. EASD Honorary Secretary Tina Vilsbøll outlines the potential of an emerging class of non-peptide GLP-1 receptor agonists for the treatment of diabetes and obesity. She then highlights brand new data from the ACHIEVE-1 phase 3 RCT with orfoglipron, that were simultaneously published in the New England Journal of Medicine. 

Interviewees:  

• Prof. Simon Heller, University of Sheffield 
• Prof. Richard Oram, University of Exeter 
• Prof. Tina Vilsbøll, University of Copenhagen 

Staff: 

• Interviewer: Dr Albert Brugger
• Videographer: Christian Fichtner, Bsc